The National Institute for Health and Care Excellence (NICE) recently published its HTE24 guidance under the Health Technology Evaluation (HTE) programme, marking a milestone for artificial intelligence in dermatology. At the centre of this …
In an era defined by digital health transformation and data-driven care, Finland continues to lead in diagnostic interoperability, public reimbursement integration and laboratory standardisation. At the heart of this ecosystem …
Rethinking Reimbursement: France’s Article 51 as a Model for Real-World Innovation In 2018, France introduced a powerful tool to reshape its health system from within: Article 51 of the Loi de Financement de …
In the two decades since the arrival of robotic-assisted surgery (RAS), clinical teams across urology, colorectal, gynaecological and orthopaedic domains have embraced its ergonomic advantages, precision tooling and potential for …
Melanoma has seen an extraordinary therapeutic revolution over the past decade, with immune checkpoint inhibitors (e.g. nivolumab, pembrolizumab, ipilimumab) and BRAF/MEK inhibitors (e.g. dabrafenib/trametinib, vemurafenib/cobimetinib) substantially improving survival. However, the …
The National Institute for Health and Care Excellence (NICE) has recently updated its Real-World Evidence (RWE) Framework, formally recognising qualitative research as an important contributor to health technology assessment (HTA) in England. This …
In January 2024, the Dutch National Health Care Institute (Zorginstituut Nederland) published a comprehensive update to its Guideline for Economic Evaluations in Healthcare, the first since 2016. More than just a procedural …
The reimbursement of orphan medicinal products (OMPs) for rare diseases remains one of the most complex challenges in European healthcare policy. These therapies frequently launch with limited clinical evidence, small target populations …
The UK is entering a bold new chapter in how innovative medicines and diagnostics reach patients, and it’s one that could re-define the global standard. With a series of strategic …
How do we measure How healthy’ someone really is? And how do we turn that into numbers that help shape health policy, pricing decisions and even drug approvals? That’s where the EQ-5D-5L comes …